- Home
- BRT vs TSHA Comparison
BRT vs TSHA Comparison
Compare BRT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- TSHA
- Stock Information
- Founded
- BRT 1972
- TSHA 2019
- Country
- BRT United States
- TSHA United States
- Employees
- BRT N/A
- TSHA N/A
- Industry
- BRT Real Estate Investment Trusts
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- TSHA Health Care
- Exchange
- BRT Nasdaq
- TSHA Nasdaq
- Market Cap
- BRT 331.7M
- TSHA 356.7M
- IPO Year
- BRT N/A
- TSHA 2020
- Fundamental
- Price
- BRT $18.28
- TSHA $1.67
- Analyst Decision
- BRT Strong Buy
- TSHA Strong Buy
- Analyst Count
- BRT 3
- TSHA 8
- Target Price
- BRT $22.17
- TSHA $6.63
- AVG Volume (30 Days)
- BRT 26.7K
- TSHA 1.7M
- Earning Date
- BRT 03-12-2025
- TSHA 05-13-2025
- Dividend Yield
- BRT 5.51%
- TSHA N/A
- EPS Growth
- BRT N/A
- TSHA N/A
- EPS
- BRT N/A
- TSHA N/A
- Revenue
- BRT $97,274,000.00
- TSHA $8,333,000.00
- Revenue This Year
- BRT $5.43
- TSHA N/A
- Revenue Next Year
- BRT $5.39
- TSHA N/A
- P/E Ratio
- BRT N/A
- TSHA N/A
- Revenue Growth
- BRT 1.65
- TSHA N/A
- 52 Week Low
- BRT $15.81
- TSHA $1.19
- 52 Week High
- BRT $20.22
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- BRT 55.69
- TSHA 43.73
- Support Level
- BRT $17.75
- TSHA $1.59
- Resistance Level
- BRT $18.50
- TSHA $1.87
- Average True Range (ATR)
- BRT 0.65
- TSHA 0.10
- MACD
- BRT 0.02
- TSHA -0.01
- Stochastic Oscillator
- BRT 57.57
- TSHA 8.93
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.